Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

Alfonso H. Santos, Michael J. Casey, Charles M. Bucci, Shehzad Rehman, Mark S. Segal

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In hypertensive kidney transplant recipients, the effects of nebivolol vs metoprolol on nitric oxide (NO) blood level, estimated glomerular filtration rate (eGFR), and blood pressure (BP) have not been previously reported. In a 12-month prospective, randomized, open-label, active-comparator trial, hypertensive kidney transplant recipients were treated with nebivolol (n=15) or metoprolol (n=15). Twenty-nine patients (nebivolol [n=14], metoprolol [n=15]) completed the trial. The primary endpoint was change in blood NO level after 12 months of treatment. Secondary endpoints were changes in eGFR, BP, and number of antihypertensive drug classes used. After 12 months of treatment, least squares mean change in plasma NO level in the nebivolol kidney transplant recipient group younger than 50 years was higher by 68.19% (99.17% confidence interval [CI], 13.02–123.36), 69.54% (99.17% CI, 12.71–126.37), and 66.80% (99.17% CI, 12.95–120.64) compared with the metoprolol group younger than 50 years, the metoprolol group 50 years and older, and the nebivolol group 50 years and older, respectively. The baseline to month 12 change in mean arterial BP, eGFR, and number of antihypertensive drug classes used was not significantly different between the treatment groups. In hypertensive kidney transplant recipients, nebivolol use in patients younger than 50 years increased blood NO.

Original languageEnglish (US)
Pages (from-to)741-749
Number of pages9
JournalJournal of Clinical Hypertension
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Nebivolol
Metoprolol
Nitric Oxide
Blood Pressure
Transplants
Kidney
Glomerular Filtration Rate
Confidence Intervals
Antihypertensive Agents
Arterial Pressure
Least-Squares Analysis
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients. / Santos, Alfonso H.; Casey, Michael J.; Bucci, Charles M.; Rehman, Shehzad; Segal, Mark S.

In: Journal of Clinical Hypertension, Vol. 18, No. 8, 01.08.2016, p. 741-749.

Research output: Contribution to journalArticle

Santos, Alfonso H. ; Casey, Michael J. ; Bucci, Charles M. ; Rehman, Shehzad ; Segal, Mark S. / Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients. In: Journal of Clinical Hypertension. 2016 ; Vol. 18, No. 8. pp. 741-749.
@article{dd2f9c0713c5429695b7114190a68307,
title = "Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients",
abstract = "In hypertensive kidney transplant recipients, the effects of nebivolol vs metoprolol on nitric oxide (NO) blood level, estimated glomerular filtration rate (eGFR), and blood pressure (BP) have not been previously reported. In a 12-month prospective, randomized, open-label, active-comparator trial, hypertensive kidney transplant recipients were treated with nebivolol (n=15) or metoprolol (n=15). Twenty-nine patients (nebivolol [n=14], metoprolol [n=15]) completed the trial. The primary endpoint was change in blood NO level after 12 months of treatment. Secondary endpoints were changes in eGFR, BP, and number of antihypertensive drug classes used. After 12 months of treatment, least squares mean change in plasma NO level in the nebivolol kidney transplant recipient group younger than 50 years was higher by 68.19{\%} (99.17{\%} confidence interval [CI], 13.02–123.36), 69.54{\%} (99.17{\%} CI, 12.71–126.37), and 66.80{\%} (99.17{\%} CI, 12.95–120.64) compared with the metoprolol group younger than 50 years, the metoprolol group 50 years and older, and the nebivolol group 50 years and older, respectively. The baseline to month 12 change in mean arterial BP, eGFR, and number of antihypertensive drug classes used was not significantly different between the treatment groups. In hypertensive kidney transplant recipients, nebivolol use in patients younger than 50 years increased blood NO.",
author = "Santos, {Alfonso H.} and Casey, {Michael J.} and Bucci, {Charles M.} and Shehzad Rehman and Segal, {Mark S.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/jch.12745",
language = "English (US)",
volume = "18",
pages = "741--749",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

AU - Santos, Alfonso H.

AU - Casey, Michael J.

AU - Bucci, Charles M.

AU - Rehman, Shehzad

AU - Segal, Mark S.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - In hypertensive kidney transplant recipients, the effects of nebivolol vs metoprolol on nitric oxide (NO) blood level, estimated glomerular filtration rate (eGFR), and blood pressure (BP) have not been previously reported. In a 12-month prospective, randomized, open-label, active-comparator trial, hypertensive kidney transplant recipients were treated with nebivolol (n=15) or metoprolol (n=15). Twenty-nine patients (nebivolol [n=14], metoprolol [n=15]) completed the trial. The primary endpoint was change in blood NO level after 12 months of treatment. Secondary endpoints were changes in eGFR, BP, and number of antihypertensive drug classes used. After 12 months of treatment, least squares mean change in plasma NO level in the nebivolol kidney transplant recipient group younger than 50 years was higher by 68.19% (99.17% confidence interval [CI], 13.02–123.36), 69.54% (99.17% CI, 12.71–126.37), and 66.80% (99.17% CI, 12.95–120.64) compared with the metoprolol group younger than 50 years, the metoprolol group 50 years and older, and the nebivolol group 50 years and older, respectively. The baseline to month 12 change in mean arterial BP, eGFR, and number of antihypertensive drug classes used was not significantly different between the treatment groups. In hypertensive kidney transplant recipients, nebivolol use in patients younger than 50 years increased blood NO.

AB - In hypertensive kidney transplant recipients, the effects of nebivolol vs metoprolol on nitric oxide (NO) blood level, estimated glomerular filtration rate (eGFR), and blood pressure (BP) have not been previously reported. In a 12-month prospective, randomized, open-label, active-comparator trial, hypertensive kidney transplant recipients were treated with nebivolol (n=15) or metoprolol (n=15). Twenty-nine patients (nebivolol [n=14], metoprolol [n=15]) completed the trial. The primary endpoint was change in blood NO level after 12 months of treatment. Secondary endpoints were changes in eGFR, BP, and number of antihypertensive drug classes used. After 12 months of treatment, least squares mean change in plasma NO level in the nebivolol kidney transplant recipient group younger than 50 years was higher by 68.19% (99.17% confidence interval [CI], 13.02–123.36), 69.54% (99.17% CI, 12.71–126.37), and 66.80% (99.17% CI, 12.95–120.64) compared with the metoprolol group younger than 50 years, the metoprolol group 50 years and older, and the nebivolol group 50 years and older, respectively. The baseline to month 12 change in mean arterial BP, eGFR, and number of antihypertensive drug classes used was not significantly different between the treatment groups. In hypertensive kidney transplant recipients, nebivolol use in patients younger than 50 years increased blood NO.

UR - http://www.scopus.com/inward/record.url?scp=84952700532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952700532&partnerID=8YFLogxK

U2 - 10.1111/jch.12745

DO - 10.1111/jch.12745

M3 - Article

C2 - 26692375

AN - SCOPUS:84952700532

VL - 18

SP - 741

EP - 749

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 8

ER -